WO2014132270A2 - Procédé de préparation de monochlorydrate d'acétamide 2- (2-aminothiazol -4-yl)-n- [4- (2- {[ (2r) -2-hydroxy -2-phényl-éthyl] amino} éthyl) phényl], de ses intermédiaires et polymorphe de celui-ci - Google Patents
Procédé de préparation de monochlorydrate d'acétamide 2- (2-aminothiazol -4-yl)-n- [4- (2- {[ (2r) -2-hydroxy -2-phényl-éthyl] amino} éthyl) phényl], de ses intermédiaires et polymorphe de celui-ci Download PDFInfo
- Publication number
- WO2014132270A2 WO2014132270A2 PCT/IN2014/000129 IN2014000129W WO2014132270A2 WO 2014132270 A2 WO2014132270 A2 WO 2014132270A2 IN 2014000129 W IN2014000129 W IN 2014000129W WO 2014132270 A2 WO2014132270 A2 WO 2014132270A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- ethyl
- phenyl
- solvents
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 230000008569 process Effects 0.000 title claims abstract description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims description 79
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 title claims description 33
- 239000000543 intermediate Substances 0.000 title abstract description 3
- -1 2-(2-aminothiazol-4-yl)- N-[4-(2- {[(2R)-2-hydroxy-2-phenylethyl]amino} ethyl)phenyl]acetamide monohydrochloride compound Chemical class 0.000 claims abstract description 169
- 239000002904 solvent Substances 0.000 claims description 111
- 150000001875 compounds Chemical class 0.000 claims description 104
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 239000003638 chemical reducing agent Substances 0.000 claims description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 20
- 239000007822 coupling agent Substances 0.000 claims description 18
- 239000002585 base Substances 0.000 claims description 17
- 239000002798 polar solvent Substances 0.000 claims description 17
- 239000012279 sodium borohydride Substances 0.000 claims description 17
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 17
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 15
- 239000004215 Carbon black (E152) Substances 0.000 claims description 15
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 15
- 239000003759 ester based solvent Substances 0.000 claims description 15
- 239000004210 ether based solvent Substances 0.000 claims description 15
- 229930195733 hydrocarbon Natural products 0.000 claims description 15
- 150000002430 hydrocarbons Chemical class 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 230000001476 alcoholic effect Effects 0.000 claims description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 14
- 230000002378 acidificating effect Effects 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 239000003880 polar aprotic solvent Substances 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 8
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 8
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 claims description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- 239000001119 stannous chloride Substances 0.000 claims description 8
- ZGJGVOWYPHPPFA-FYZYNONXSA-N 2-(2-amino-1,3-thiazol-4-yl)-n-[4-[2-[[(2r)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide;hydrochloride Chemical compound Cl.S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 ZGJGVOWYPHPPFA-FYZYNONXSA-N 0.000 claims description 7
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 claims description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 7
- 238000006268 reductive amination reaction Methods 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 claims description 6
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 6
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 6
- 238000011065 in-situ storage Methods 0.000 claims description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- 239000012448 Lithium borohydride Substances 0.000 claims description 4
- 239000007868 Raney catalyst Substances 0.000 claims description 4
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 239000012296 anti-solvent Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000000428 dust Substances 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 239000005453 ketone based solvent Substances 0.000 claims description 4
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 239000010948 rhodium Substances 0.000 claims description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 4
- 229910001023 sodium amalgam Inorganic materials 0.000 claims description 4
- 235000011150 stannous chloride Nutrition 0.000 claims description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 3
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims description 3
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 229910010084 LiAlH4 Inorganic materials 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 claims description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 3
- 150000004679 hydroxides Chemical group 0.000 claims description 3
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-N iron;hydrochloride Chemical compound Cl.[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims 2
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 claims 2
- VVZHIPJIQZRNSM-MRXNPFEDSA-N (1R)-1-[2-(4-nitrophenyl)ethylamino]-1-phenylethanol Chemical compound C[C@](O)(NCCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 VVZHIPJIQZRNSM-MRXNPFEDSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 description 70
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000007787 solid Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 11
- YWGDTDSOHPHFAQ-OAHLLOKOSA-N (2r)-2-hydroxy-n-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide Chemical compound O=C([C@H](O)C=1C=CC=CC=1)NCCC1=CC=C([N+]([O-])=O)C=C1 YWGDTDSOHPHFAQ-OAHLLOKOSA-N 0.000 description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 10
- 238000002411 thermogravimetry Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 0 *CCc(cc1)ccc1[N+]([O-])=O Chemical compound *CCc(cc1)ccc1[N+]([O-])=O 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 229960001551 mirabegron Drugs 0.000 description 4
- 238000001144 powder X-ray diffraction data Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- TUAHDMSPHZSMQN-INIZCTEOSA-N (1r)-2-[2-(4-aminophenyl)ethylamino]-1-phenylethanol Chemical compound C1=CC(N)=CC=C1CCNC[C@H](O)C1=CC=CC=C1 TUAHDMSPHZSMQN-INIZCTEOSA-N 0.000 description 2
- AJKDCDVYVOGLGP-QHCPKHFHSA-N (1r)-2-[benzyl-[2-(4-nitrophenyl)ethyl]amino]-1-phenylethanol Chemical compound C([C@H](O)C=1C=CC=CC=1)N(CC=1C=CC=CC=1)CCC1=CC=C([N+]([O-])=O)C=C1 AJKDCDVYVOGLGP-QHCPKHFHSA-N 0.000 description 2
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 2
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
- DYCLHZPOADTVKK-UHFFFAOYSA-N 2-(2-azaniumyl-1,3-thiazol-4-yl)acetate Chemical compound NC1=NC(CC(O)=O)=CS1 DYCLHZPOADTVKK-UHFFFAOYSA-N 0.000 description 2
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- YIBHHPKCUYKTTB-UHFFFAOYSA-N n-benzyl-2-(4-nitrophenyl)ethanamine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCNCC1=CC=CC=C1 YIBHHPKCUYKTTB-UHFFFAOYSA-N 0.000 description 2
- 208000020629 overactive bladder Diseases 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NUMQCACRALPSHD-UHFFFAOYSA-N tert-butyl ethyl ether Chemical compound CCOC(C)(C)C NUMQCACRALPSHD-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LUAUJCGKCGBAKA-NTISSMGPSA-N (1r)-2-[2-(4-nitrophenyl)ethylamino]-1-phenylethanol;hydrochloride Chemical compound Cl.C([C@H](O)C=1C=CC=CC=1)NCCC1=CC=C([N+]([O-])=O)C=C1 LUAUJCGKCGBAKA-NTISSMGPSA-N 0.000 description 1
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SSORSZACHCNXSJ-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)-3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound ClC=1C=C(C=CC=1Cl)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NCC(C)O SSORSZACHCNXSJ-UHFFFAOYSA-N 0.000 description 1
- DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- NJBCRXCAPCODGX-UHFFFAOYSA-N 2-methyl-n-(2-methylpropyl)propan-1-amine Chemical compound CC(C)CNCC(C)C NJBCRXCAPCODGX-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- SJVGFKBLUYAEOK-SFHVURJKSA-N 6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile Chemical compound FC=1C=C(C=C(C=1)F)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N SJVGFKBLUYAEOK-SFHVURJKSA-N 0.000 description 1
- AWMVMTVKBNGEAK-QMMMGPOBSA-N C1O[C@@H]1c1ccccc1 Chemical compound C1O[C@@H]1c1ccccc1 AWMVMTVKBNGEAK-QMMMGPOBSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- FJCCWUVWFDOSAU-UHFFFAOYSA-N [O-][N+](NCc1ccccc1)=O Chemical compound [O-][N+](NCc1ccccc1)=O FJCCWUVWFDOSAU-UHFFFAOYSA-N 0.000 description 1
- GXTZAIGFWQRDSQ-INIZCTEOSA-N [O-][N+](c1ccc(CCNC[C@@H](c2ccccc2)O)cc1)=O Chemical compound [O-][N+](c1ccc(CCNC[C@@H](c2ccccc2)O)cc1)=O GXTZAIGFWQRDSQ-INIZCTEOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 229940075931 sodium dithionate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention provides 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl]amino ⁇ ethyl)phenyl]acetamide monohydrochloride salt compound of formula- la, its hydrates, polymorphs and rocess for preparation thereof.
- the present invention also provides an improved process for the preparation of 2-(2- amino thiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide compound of formula- 1.
- Background of the invention :
- 2-(2-Aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl] acetamide commonly known as Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. It was developed by Astellas Pharma and was approved in the United States on 28 th June 2012 and in Europe on 20 th Dec. 2012.
- the said patent discloses a process for the preparation of dihydrochloride salt of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl]amino ⁇ ethyl)phenyl] acetamide, which comprising of deprotection of tert-butyl (R)- N-[2-[4-[2-(2-amino-thiazol-4-yl)acetamido]phenyl]ethyl]-N-[(2-hydroxy-2-phenyl)ethyl] carbamate (Boc protected Mirabegron) with hydrochloric acid in a mixture of methanol and ethyl acetate followed by purification of the obtained Mirabegron by reverse phase column chromatography using water/methanol (2: 1) as eluent.
- Polymorphs are distinct solids having the same molecular formula yet having distinct advantageous physical properties compared to other polymorphic forms of the same compound.
- the difference in the physical properties of different polymorphic forms results from the orientation and intermolecular interactions of adjacent molecules in the bulk solid.
- Polymorphism the occurrence of different crystal forms, is a property of some molecules and molecular complexes.
- a single molecule may give rise to a variety of polymorphic forms having distinct crystal structures and physical properties like melting point, X-ray diffraction pattern, infrared absorption and solid state NMR spectrum.
- One polymorphic form may give rise to thermal behavior different from that of another polymorphic form. Thermal behavior can be measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) as well as content of solvent in the polymorphic form, which have been used to distinguish polymorphic forms.
- TGA thermogravimetric analysis
- DSC differential scanning calorimetry
- the first aspect of the present invention is to provide monohydrochloride salt of 2-(2- aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide.
- the second aspect of the present invention is to provide crystalline form of 2-(2- aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide monohydrochloride compound of formula- la, herein after referred as crystalline form-M.
- the third aspect of the present invention is to provide a process for the preparation of 2- (2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide monohydrochloride salt compound of formula- la.
- the fourth aspect of the present invention is to provide a process for the preparation of N-benzyl-2-(4-nitrophenyl)ethanamine compound of formula-8, comprising of reductive amination of benzaldehyde with 2-(4-nitrophenyl)ethanamine compound of formula-3 to provide N-benzyl-2-(4-nitrophenyl)ethanamine compound of formula-8.
- the fifth aspect of the present invention is to provide another process for the preparation of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl )phenyl] acetamide monohydrochloride salt compound of formula- 1 a.
- the sixth aspect of the present invention is to provide a process for the preparation of (2- aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide compound of formula- 1.
- Figure-1 Illustrates the PXRD pattern of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl] amino ⁇ ethyl)phenyl]acetamide monohydrochloride (Formula- 1 a).
- Figure-2 Illustrates the DSC thermogram of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2- hydroxy-2-phenylethyl] amino ⁇ ethyl)phenyl] acetamide monohydrochloride (Formula- 1 a) .
- FIG. 3 Illustrates the thermogravimetric analysis (TGA) curve of 2-(2-aminothiazol-4-yl)-N- [4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide monohydrochloride (Formula- la).
- TGA thermogravimetric analysis
- Figure-4 Illustrates the PXRD pattern of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl]amino ⁇ ethyl)phenyl]acetamide monohydrochloride (Formula- la) obtained according to example- 15.
- Figure-5 Illustrates the PXRD pattern of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl]amino ⁇ ethyl)phenyl]acetamide (Formula-1).
- suitable solvent refers to "hydrocarbon solvents” such as n-pentane, n-hexane, n-heptane, cyclohexane, methyl cyclohexane, cycloheptane, pet ether, chlorobenzene, toluene, xylene and the like; "ether solvents” such as dimethyl ether, diethyl ether, diisopropyl ether, methyl tert-butyl ether, ethyl tert-butyl ether, di- tert-butyl ether, dimethoxy methane, 1,2-dimethoxy ethane (monoglyme), diglyme, 1,4- dioxane, tetrahydrofuran, 2-methyl tetrahydrofuran, morpholine and the like; "ester solvents” such as methyl acetate, ethyl acetate,
- suitable base refers to "alkali metal carbonates” such as sodium carbonate, potassium carbonate, lithium carbonate and the like; “alkali metal bicarbonates” such as sodium bicarbonate, potassium bicarbonate and the like; “alkali metal hydroxides” such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; “alkali metal alkoxides” such as sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium tert.butoxide, potassium tert.butoxide and the like; “alkali metal hydrides” such as sodium hydride, potassium hydride and the like; “alkali metal amides” such as sodium amide, potassium amide, lithium amide, lithium diisopropyl amide (LDA) and the like; “alkali metal phosphates” such as disodium hydrogen phosphate, dipotassiumhydrogen phosphate; and “organic bases”
- the first aspect of the present invention provides monohydrochloride salt of 2-(2- aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide.
- the said monohydrochloride salt of the present invention can exists in the form of
- the second aspect of the present invention provides crystalline form of 2-(2- aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide monohydrochloride salt compound of formula- la characterized by its powder X-ray diffraction pattern having peaks at 2.1, 4.3, 6.4, 8.5, 17.4, 19.3, 21.6, 24.3, 24.8, 27.3, 31.6, 45.4 ⁇ 0.2 degrees of 2-theta.
- the said crystalline form is herein after designated as crystalline form-M.
- the said crystalline form-M is further characterized by its PXRD pattern as illustrated in figure- 1 and its differential scanning calorimetric (DSC) thermogram having an endotherm at 201.03°C substantially in accordance with figure-2.
- the third aspect of the present invention provides a process for the preparation of 2-(2- aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide monohydrochloride salt compound of formula- 1 a, comprising of;
- step-(e) treating the dihydrochloride salt obtained in step-(e) in-situ with a suitable aqueous base to provide 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl) phenyl] acetamide monohydrochloride salt compound of formula- la.
- the suitable coupling agent is selected form N,N-carbonyldiimidazole (CDI); alkyl and aryl carbodiimides such as ⁇ , ⁇ -diisopropylcarbodiimide (DIC), N,N- dicyclohexyl carbodiimide (DCC), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HC1), ditolyl carbodiimide optionally in combination with hydroxybenzotriazole or N-hydroxysuccinimide (NHS) or N-hydroxysulfosuccinimide (Sulfo- NHS); carbonyl-di-l,2,4-triazole; alkyl and aryl halo formates such as ethyl chloroformate, phenyl chloroformate, benzyl chloroformate; carbonates having the formula R1-O-CO-O-R2, where
- the suitable reducing agent is selected from diborane, borane-dimethyl sulfide, borane-THF complex, sodium triacetoxyborohydride, sodium cyanoborohydride, NaBH 4 , NaBH 4 /BF 3 .diethyl ether, LiBH 4 , LiAlH 4 and the like; and the suitable solvent is selected from alcoholic solvent, ether solvents, ester solvents, hydrocarbon solvents, polar solvents, polar aprotic solvents or mixtures thereof;
- step-c) the conversion of compound of formula-5 into its HCl salt compound of formula-5a is carried out by using a suitable HCl source selected from HCl gas, HCl, aq.HCl, ethylacetate-HCl and IPA-HC1 in a suitable solvent.
- a suitable HCl source selected from HCl gas, HCl, aq.HCl, ethylacetate-HCl and IPA-HC1 in a suitable solvent.
- the suitable reducing agent is selected from Fe, Fe in acidic media like NH 4 C1 or HCl or acetic acid, Sn in acidic media like HCl, Zn dust, Zn in acidic media like HCl or NH 4 CI or acetic acid, stannous chloride (SnCl 2 ), NaB3 ⁇ 4, LiAlH 4i LiBH 4 , diborane, borane-THF complex, hydrazine hydrate, hydrogenation catalysts such as Pd/C, Pt/C, Pt0 2 , Pd(OH) 2 , Nickel, Raney nickel, Rhodium, sodium dithionate, sodium amalgam and the like; the suitable solvent is selected from alcoholic solvents, ether solvents, ester solvents, polar solvents, hydrocarbon solvents or mixtures thereof;
- step-e) the suitable coupling agent & suitable solvent are same as defined in step-(a); in step-f) the suitable base can be selected from hydroxides, carbonates and bicarbonates of alkali metals.
- a preferred embodiment of the present invention provides a process for the preparation of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-henylethyl]amino ⁇ ethyl)phenyl]acetamide mono hydrochloride salt compound of formula- la, comprising of;
- step-(e) treating the dihydrochloride salt obtained in step-(e) in-situ with aqueous sodium hydroxide solution to provide 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl] amino ⁇ ethyl)phenyl]acetamide monohydrochloride compound of formula- la.
- US7342117B2 patent discloses the reduction of (R)-2-hydroxy-N-(4-nitrophenethyl)-2- phenylacetamide compound of formula-4 to (R)-2-(4-nitrophenethylamino)-l-phenylethanol compound of formula-5 using borane-THF complex in a mixture of l,3-dimethyl-2- imidazolidinone (DMI) and tetrahydrofuran.
- DMI 1, 3 -dimethyl-2 -imidazolidinone
- DI 1, 3 -dimethyl-2 -imidazolidinone
- the present inventors carried out the said reduction step in tetrahydrofuran, thereby avoiding the usage of toxic and high boiling solvents like l,3-dimethyl-2-imidazolidinone (DMI), hence the process of the present invention is advantageous over prior-art process.
- DMI toxic and high boiling solvents like l,3-dimethyl-2-imidazolidinone
- the 2-(4-nitrophenyl)ethanamine compound of formula-3 utilized in step-(a) of the third aspect of the present invention can be synthesized by any of the prior reported processes, for example it can be synthesized by the processes disclosed in J. Org. Chem., 1978, 43(1), 31-33 and Tetrahedron Letters, Volume 10, Issue 52, 1969, 4555-4558.
- the 2-(2-aminothiazol-4-yl)acetic acid compound of formula-7 utilized in step-(e) of the third aspect of the present invention can be synthesized by any of the processes known in the art such as US4391979A.
- the fourth aspect of the present invention provides a process for the preparation of N- benzyl-2-(4-nitrophenyl)ethanamine compound of formula-8,
- the reductive amination step is carried out in presence of a suitable reducing agent selected form NaBH 4 , sodium cyanoborohydride, sodium triacetoxyborohydride, trihalosilanes, diisobutylaluminium hydride (DIBAL), lithium triethylborohydride, lithium tri- sec-butyl borohydride (L-selectride), trialkylsilanes optionally in combination with trifluoroacetic acid, hydrogenating agents like Pd/C, Pt/C, Ni, Raney Ni and the like in a suitable solvent selected from alcoholic solvents, ether solvents, ester solvents, polar solvents, hydrocarbon solvents, polar-aprotic solvents or mixtures thereof.
- a suitable reducing agent selected form NaBH 4 , sodium cyanoborohydride, sodium triacetoxyborohydride, trihalosilanes, diisobutylaluminium hydride (DIBAL), lithium triethylborohydride,
- a preferred embodiment of the present invention provides a process for the preparation of N-benzyl-2-(4-nitrophenyl)ethanamine compound of formula-8, comprising of reductive amination of benzaldehyde with 2-(4-nitrophenyl)ethanamine compound of formula-3 in presence of sodium borohydride in methanol to provide N-benzyl-2-(4-nitrophenyl)ethanamine compound of formula-8.
- the fifth aspect of the present invention provides a process for the preparation of 2-(2- aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide monohydrochloride salt compound of formula- la, comprising of;
- suitable reducing agent and the suitable solvent are same as defined in fourth aspect of the present invention; in step-b) the suitable solvent is selected from alcoholic solvents, ether solvents, ester solvents, polar solvents, hydrocarbon solvents, ketone solvent, polar-aprotic solvents or mixtures thereof;
- the suitable reducing agent is selected from Pd/C, Pt/C, Raney Ni, Pt0 2 and the like; and the suitable solvent is selected from alcoholic solvents, ether solvents, ester solvents, polar solvents, hydrocarbon solvents or mixtures thereof;
- step-d) the suitable coupling agent and suitable solvent are same as defined in step-(a) of the third aspect of the present invention.
- step-e) the suitable base is same as defined for step-(f) of the third aspect of the present invention.
- the sixth aspect of the present invention provides a process for the preparation of 2-(2- aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl]acetamide compound of formula- 1, comprising of:
- step-a) the suitable coupling agent, the suitable base and suitable solvent are same as defined in step-(a) of third aspect of the present invention.
- step-b) the suitable reducing agent and suitable solvent are same as defined in step-(b) of third aspect of the present invention respectively;
- step-c) the suitable reducing agent and suitable solvent is same as defined in step-(d) of third aspect of the present invention.
- step-d) the suitable coupling agent and suitable solvents are same as defined in step-(a) of third aspect of the present invention.
- the suitable solvent is alcoholic solvents; the anti-solvent is selected from polar solvents.
- a preferred embodiment of the present invention provides a process for the preparation of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl]amino ⁇ ethyl)phenyl]acetamide compound of formula- 1, comprising of:
- step-(d) purifying the compound obtained in step-(d) by dissolving the compound in methanol followed by adding water to provide pure compound of formula- 1.
- 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl] acetamide obtained by the present invention is having purity about 99.8% by HPLC. All the impurities that are formed during the synthesis of compound of formula- 1 and its mono hydrochloride salt of formula- la are controlled to below ICH limits in which few of them are controlled to not detected level.
- a liquid chromatograph is equipped with variable wavelength UV-detector; Column: symmetry shield RP18, 250 x 4.6 mm, 5 ⁇ or equivalent; Flow rate: 1.0 ml/minute; Elution: Gradient; Wavelength: 210 nm; Column temperature: 45°C; Injection volume: 5 ⁇ ; Run time: 45 mins; Needle wash: Diluent; Diluent: water: acetonitrile (50:50 v/v); Mobile phase A: Buffer : Methanol (70: 30 v/v); Mobile phase B: Acetonitrile : Buffer (70:30 v/v); Buffer preparation: Transfer about 1.74 gms of anhydrous Di potassium hydrogen phosphate and 3 gms of anhydrous 1 -octane sulfonic acid sodium salt in 1000 ml of milli-Q-water, adjust its pH of to 5.0 with dil.ortho phosphoric acid and filter this solution through 0.22 ⁇
- DSC Differential scanning calorimetric
- TGA Thermogravimetric analysis
- 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl] acetamide and its monohydrochloride salt produced by the present invention can be further micronized or milled to get the desired particle size, preferably less than 20 ⁇ to achieve desired solubility profile based on different forms of pharmaceutical composition requirements.
- Techniques that may be used for particle size reduction include, but not limited to ball mills, roller and hammer mills and jet mills. Milling or micronization may be performed before drying or after the completion of drying of the product.
- Milling or micronization may be performed before drying or after the completion of drying of the product. The best mode of carrying out the present invention is illustrated by the below mentioned examples. These examples are provided as illustration only and hence should not be construed as limitation to the scope of the invention.
- Example-1 Preparation of (R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide (or) (R)-2-hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide (Formula-4)
- Example-2 Preparation of (R)-2-[[2'-(4-nitrophenyl)-ethyl]amino]-l-phenyIethanol mono hydrochloride (or) (R)-2-(4-nitrophenethylamino)-l-phenylethanol mono hydrochloride (Formula-5a)
- Example-3 Preparation of (R)-2-[ ⁇ 2-(4-aminophenyl)ethyI]-amino]-l-phenyIethanoI monohydrochloride (or) (R)-2-(4-aminophenethylamino)-l-phenylethanol mono hydrocloride
- Iron powder (86.8 gms) was added to a mixture of (R)-2-[[2'-(4-nitrophenyl)- ethyl] amino] -1 -phenylethanol monohydrochloride compound of formula-5a (100 gms), tetrahydrofuran (500 ml) and water (500 ml) at 25-30°C and stirred for 15 min at the same temperature.
- tetrahydrofuran 500 ml
- water 500 ml
- hydrochloric acid 124 ml
- Example-5 Preparation of 2-(2-aminothiazoI-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl] amino ⁇ ethyl)phenyl]acetamide monohydrochloride (Formula-la) 2-aminothiazol-4-yl-acetic acid (or) 2-(2-aminothiazol-4-yl)acetic acid compound of formula-7 (2.76 gms) was added to a mixture of (R)-2-[[2-(4-aminophenyl)ethyl]-amino]-l- phenylethanol monohydrochloride compound of formula-6a (5.0 gms), hydrochloric acid (4.62 ml) and water (30 ml) at 25-30°C and stirred for 15 mins at the same temperature.
- EDC.HC1 l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
- Example-6 Preparation of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl]amino ⁇ ethyI)phenyl]acetamide monohydrochloride (Formula-la)
- 2-aminothiazol-4-yl-acetic acid compound of formula-7 (5.5 gms) was added to a mixture of (R)-2-[[2-(4-aminophenyl)ethyl]-amino]-l-phenylethanol compound of formula-6 (10 gms), hydrochloric acid (3.5 gms) and water (75 ml) at 25-30°C.
- a solution of l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1) (7.5 gms of EDC.HC1 dissolved in 120 ml of water) was added slowly to the reaction mixture at 25-30°C and stirred for 3 hrs at the same temperature.
- Aqueous sodium hydroxide solution (3.13 gms of sodium hydroxide dissolved in 30 ml of water) was added to the reaction mixture and stirred for 90 mins at 25- 30°C. Filtered the precipitated solid, washed with water and dried to get title compound.
- Example-10 Preparation of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl] amino ⁇ ethyl)phenyl]acetamide monohydrochloride (Formula-la) 2-aminothiazol-4-yl-acetic acid compound of formula-7 (2.76 gms) was added to a mixture of (R)-2-[[2-(4-aminophenyl)ethyl]-amino]-l-phenylethanol compound of formula-6 (5.0 gms), hydrochloric acid (4.62 ml) and water (30 ml) at 25-30°C and stirred the reaction mixture for 15 mins at the same temperature.
- the TGA of the obtained compound is shown in figure-3, which indicates that the obtained 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl] acetamide monohydrochloride salt is anhydrous in nature.
- EDC.HCl l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
- EDC.HCl hydroxybenztriazole
- HOBt hydroxybenztriazole
- R -2-hydroxy-2-phenylacetic acid compound of formula-2
- triethylamine 49.8 gms
- 2-(4- nitrophenyl)ethylamine hydrochloride compound of formula-3a 100 gms
- N-methyl-2- pyrrolidone 400 ml
- Example-13 Preparation of (R)-2-[[2-(4-aminophenyl)ethyl]-amino]-l-phenylethanoI (Formula-6)
- l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (222.3 gms) was slowly added to the reaction mixture at 25-30°C and stirred for 3 hrs at the same temperature. Cooled the reaction mixture to 0-5°C. pH of the reaction mixture was adjusted to 9.0 using aqueous sodium hydroxide solution (66.9 gms of sodium hydroxide dissolved in 1350 ml of water) at 0-5°C and stirred for 90 mins at 0-5°C. Filtered the precipitated solid and washed with water. Water (1200 ml) was added to the obtained solid at 25-30°C and stirred for 90 mins at the same temperature.
- Chloride content 8.12% w/w; Water content: 0.27% w/w.
- Example-16 Preparation of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl] amino ⁇ ethyl)phenylJacetamide (Formula-1)
- 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2-phenylethyl]amino ⁇ ethyl)phenyl] acetamide can be prepared according to example- 14 by using 2-aminothiazol-4-yl-acetic acid hydrochloride compound of formula- 7a in place of 2-aminothiazol-4-yl-acetic acid compound of formula-7.
- Example-17 Preparation of 2-(2-aminothiazol-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy-2- phenylethyl] amino ⁇ ethyl)phenyl]acetamide (Formula- 1)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un procédé de préparation du composé monochlorhydrate d'acétamide 2- (2-aminothiazol -4-yl)-N- [4- (2- {[ (2R) -2-hydroxy -2-phényléthyl] amino} éthyl)phényl] de formule-la, de ses intermédiaires et polymorphe de celui-ci. [insérer la Formule ici]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN868/CHE/2013 | 2013-02-27 | ||
IN868CH2013 | 2013-02-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014132270A2 true WO2014132270A2 (fr) | 2014-09-04 |
WO2014132270A3 WO2014132270A3 (fr) | 2014-12-24 |
Family
ID=51428918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2014/000129 WO2014132270A2 (fr) | 2013-02-27 | 2014-02-26 | Procédé de préparation de monochlorydrate d'acétamide 2- (2-aminothiazol -4-yl)-n- [4- (2- {[ (2r) -2-hydroxy -2-phényl-éthyl] amino} éthyl) phényl], de ses intermédiaires et polymorphe de celui-ci |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014132270A2 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104230840A (zh) * | 2014-09-05 | 2014-12-24 | 安徽联创药物化学有限公司 | 米拉贝隆的合成方法 |
WO2015040605A1 (fr) * | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Forme cristalline de mirabegron |
CN105111165A (zh) * | 2015-09-14 | 2015-12-02 | 河南师范大学 | 一种米拉贝隆的制备方法 |
WO2016049749A1 (fr) * | 2014-10-01 | 2016-04-07 | Apotex Inc. | Formes solides du mirabégron |
CN106278909A (zh) * | 2016-08-12 | 2017-01-04 | 浙江华海药业股份有限公司 | 一种米拉贝隆中间体的后处理方法 |
WO2017137784A1 (fr) * | 2016-02-10 | 2017-08-17 | Egis Gyógyszergyár Zrt. | Procédé de production de mirabegron morphologiquement homogène et de monochlorhydrate de mirabegron |
WO2017149332A1 (fr) * | 2016-02-01 | 2017-09-08 | Egis Gyógyszergyár Zrt. | Co-cristal de mirabegron |
CN109456277A (zh) * | 2018-10-29 | 2019-03-12 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
CN109651290A (zh) * | 2018-10-31 | 2019-04-19 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
WO2019081972A1 (fr) | 2017-08-09 | 2019-05-02 | Saneca Pharmaceuticals A.S. | Procédé de préparation d'acide mandélique 4-nitrophényl éthylamide à partir de cyanure de 4-nitrobenzyle |
CN111205151A (zh) * | 2020-02-29 | 2020-05-29 | 深圳市祥根生物科技有限公司 | 一种布洛芬杂质i的环保制备方法 |
CN111440126A (zh) * | 2020-04-03 | 2020-07-24 | 湖南复瑞生物医药技术有限责任公司 | 一种米拉贝隆的制备方法 |
KR20210073972A (ko) * | 2019-12-11 | 2021-06-21 | 주식회사 다산제약 | (r)-2-((4-아미노페네틸)아미노)-1-페닐에탄올의 신규한 제조방법 |
CN113816864A (zh) * | 2020-06-18 | 2021-12-21 | 南京正大天晴制药有限公司 | 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1440969A1 (fr) * | 2001-10-30 | 2004-07-28 | Yamanouchi Pharmaceutical Co. Ltd. | Cristal a forme alpha ou beta d'un derive acetanilinide |
EP1559427A1 (fr) * | 2002-11-07 | 2005-08-03 | Yamanouchi Pharmaceutical Co. Ltd. | Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif |
-
2014
- 2014-02-26 WO PCT/IN2014/000129 patent/WO2014132270A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1440969A1 (fr) * | 2001-10-30 | 2004-07-28 | Yamanouchi Pharmaceutical Co. Ltd. | Cristal a forme alpha ou beta d'un derive acetanilinide |
EP1559427A1 (fr) * | 2002-11-07 | 2005-08-03 | Yamanouchi Pharmaceutical Co. Ltd. | Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015040605A1 (fr) * | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Forme cristalline de mirabegron |
CN104230840A (zh) * | 2014-09-05 | 2014-12-24 | 安徽联创药物化学有限公司 | 米拉贝隆的合成方法 |
WO2016049749A1 (fr) * | 2014-10-01 | 2016-04-07 | Apotex Inc. | Formes solides du mirabégron |
CN105111165A (zh) * | 2015-09-14 | 2015-12-02 | 河南师范大学 | 一种米拉贝隆的制备方法 |
WO2017149332A1 (fr) * | 2016-02-01 | 2017-09-08 | Egis Gyógyszergyár Zrt. | Co-cristal de mirabegron |
WO2017137784A1 (fr) * | 2016-02-10 | 2017-08-17 | Egis Gyógyszergyár Zrt. | Procédé de production de mirabegron morphologiquement homogène et de monochlorhydrate de mirabegron |
CN106278909A (zh) * | 2016-08-12 | 2017-01-04 | 浙江华海药业股份有限公司 | 一种米拉贝隆中间体的后处理方法 |
WO2018028679A1 (fr) * | 2016-08-12 | 2018-02-15 | 浙江华海药业股份有限公司 | Procédé de post-traitement pour un intermédiaire de mirabegron |
CN106278909B (zh) * | 2016-08-12 | 2022-07-15 | 浙江华海药业股份有限公司 | 一种米拉贝隆中间体的后处理方法 |
WO2019081972A1 (fr) | 2017-08-09 | 2019-05-02 | Saneca Pharmaceuticals A.S. | Procédé de préparation d'acide mandélique 4-nitrophényl éthylamide à partir de cyanure de 4-nitrobenzyle |
CN109456277B (zh) * | 2018-10-29 | 2022-04-22 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
CN109456277A (zh) * | 2018-10-29 | 2019-03-12 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
CN109651290A (zh) * | 2018-10-31 | 2019-04-19 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
CN109651290B (zh) * | 2018-10-31 | 2022-04-01 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
KR20210073972A (ko) * | 2019-12-11 | 2021-06-21 | 주식회사 다산제약 | (r)-2-((4-아미노페네틸)아미노)-1-페닐에탄올의 신규한 제조방법 |
KR102350458B1 (ko) | 2019-12-11 | 2022-01-12 | 주식회사 다산제약 | (r)-2-((4-아미노페네틸)아미노)-1-페닐에탄올의 신규한 제조방법 |
CN111205151A (zh) * | 2020-02-29 | 2020-05-29 | 深圳市祥根生物科技有限公司 | 一种布洛芬杂质i的环保制备方法 |
CN111440126A (zh) * | 2020-04-03 | 2020-07-24 | 湖南复瑞生物医药技术有限责任公司 | 一种米拉贝隆的制备方法 |
CN111440126B (zh) * | 2020-04-03 | 2023-11-28 | 湖南复瑞生物医药技术有限责任公司 | 一种米拉贝隆的制备方法 |
CN113816864A (zh) * | 2020-06-18 | 2021-12-21 | 南京正大天晴制药有限公司 | 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法 |
CN113816864B (zh) * | 2020-06-18 | 2024-03-29 | 南京正大天晴制药有限公司 | 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2014132270A3 (fr) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014132270A2 (fr) | Procédé de préparation de monochlorydrate d'acétamide 2- (2-aminothiazol -4-yl)-n- [4- (2- {[ (2r) -2-hydroxy -2-phényl-éthyl] amino} éthyl) phényl], de ses intermédiaires et polymorphe de celui-ci | |
US10532982B2 (en) | Processes and intermediates in the preparation of C5aR antagonists | |
CA2859191C (fr) | Procede pour la preparation de sel derive de diamine optiquement actif | |
US20170189394A1 (en) | Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts | |
US9440979B2 (en) | Process for the preparation of pralatrexate | |
US10144714B2 (en) | Methods of making protein deacetylase inhibitors | |
US20200369652A1 (en) | Processes for preparation of lifitegrast and intermediates thereof | |
KR102396059B1 (ko) | 신규 화합물 및 이의 제조방법 | |
US10508075B2 (en) | Process for preparation of trientine dihydrochloride | |
EP3412666A1 (fr) | Procédé et intermédiaires pour la préparation d'inhibiteurs de bcl-2 comprenant du venetoclax par amination réductrice | |
US20210387990A1 (en) | Method for producing dimethoxybenzene compound | |
CN107810189B (zh) | 用于制备氮芥衍生物的方法 | |
DK2890684T3 (en) | URINARY COMPOUNDS AND THEIR USE AS ENZYMINE INHIBITORS | |
WO2013065063A1 (fr) | Forme anhydre du dasatinib, son procédé de préparation et son utilisation | |
WO2017002131A1 (fr) | Formes cristallines de n-(2-chloro-6-méthylphényl)-2-[[6-[4-(2-hydroxyéthyl)-1-pipérazinyl]-2-méthyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide et leurs procédés associés | |
WO2011065420A1 (fr) | Procédé de fabrication d'un dérivé de 1-méthyl-1h-benzimidazole substitué en 6 et intermédiaire de fabrication issu de ce procédé | |
US11149041B2 (en) | Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium) | |
CA3006537A1 (fr) | Procede de preparation de lisdexamphetamine | |
US20180079715A1 (en) | Method for producing alkylamine derivative and its production intermediate of alkylamine derivative | |
JP2010090031A (ja) | 二環性プロリン化合物の製造方法 | |
CA2421550C (fr) | Procede de preparation de midodrine, sels pharmaceutiquement acceptables a base de midodrine et intermediaires | |
JP2024080578A (ja) | ミラベグロン及びその製造中間体の製造方法 | |
WO2019073427A1 (fr) | Procédé de préparation de dichlorhydrate de trientine | |
US20150051405A1 (en) | New 1,2,4-oxadiazol derivatives, process for their preparation and use thereof as intermediates in the preparation of indolic alkaloids | |
WO2014167578A2 (fr) | Nouveau polymorphe du chlorhydrate de l'ester 2-((r)-3-diisopropylamino-1-phénylpropyl)-4-(hydroxyméthyl)phénylique de l'acide isobutyrique et son procédé de préparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14757737 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14757737 Country of ref document: EP Kind code of ref document: A2 |